Clinical Trial Update: Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of blinatumomab with a tyrosine kinase inhibitor in Philadelphia chromosome-positive acute lymphoblasti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Tyrosine kinase inhibitor (unspecified)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING